Across TCGA pan-cancer cohorts, KRTAP12-2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRTAP12-2 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KRTAP12-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP12-2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, LUAD, and LUSC are the cancer types where KRTAP12-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUAD	OS	Median	III,IV	0.068	0.680	<.001	12	view →
LUSC	OS	Median	All	0.249	0.662	.006	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.218	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KRTAP12-2 tumor-vs-normal RNA expression · all KRTAP12-2 data types